AR035978A1 - Proceso para preparar imipenem - Google Patents

Proceso para preparar imipenem

Info

Publication number
AR035978A1
AR035978A1 ARP020101831A ARP020101831A AR035978A1 AR 035978 A1 AR035978 A1 AR 035978A1 AR P020101831 A ARP020101831 A AR P020101831A AR P020101831 A ARP020101831 A AR P020101831A AR 035978 A1 AR035978 A1 AR 035978A1
Authority
AR
Argentina
Prior art keywords
formula
imipenem
ester
thienamicin
situ
Prior art date
Application number
ARP020101831A
Other languages
English (en)
Inventor
Velayudhan Nair Gopa Kumar
Neera Tewali
Bishwa Prakash Rai
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of AR035978A1 publication Critical patent/AR035978A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente se relaciona con un proceso de efectividad en el costo e industrialmente ventajoso para preparar el antibiótico imipenem de la fórmula (1). El proceso comprende: a) activar un compuesto de éster ceto de la fórmula (2) en donde R es un grupo protector con un halidato de fósforo de la fórmula (3) en donde X es un átomo halógeno y R' es un aril, ante la presencia de una base y una cantidad catalítica de una dialquil-aminopiridina para obtener el compuesto enolfosfato de la fórmula (4); b) reaccionar el intermediario de fosfato enol de la fórmula (4), in situ con 2-aminoetanotiol o una sal aditiva del ácido del mismo para obtener éster de tienamicina de la fórmula (5); c) reaccionar el éster de tienamicina de la fórmula (5) in situ con formimidato benzil o una sal aditiva del ácido del mismo ante la presencia de una base para obtener imipenem protegido con carboxilo de la fórmula (6); y d) hidrogenar el imipenem protegido con carboxilo de la fórmula (6) en un medio acuoso para obtener el imipenem.
ARP020101831A 2001-05-18 2002-05-17 Proceso para preparar imipenem AR035978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN594DE2001 2001-05-18

Publications (1)

Publication Number Publication Date
AR035978A1 true AR035978A1 (es) 2004-07-28

Family

ID=11097061

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101831A AR035978A1 (es) 2001-05-18 2002-05-17 Proceso para preparar imipenem

Country Status (19)

Country Link
US (1) US7462712B2 (es)
EP (1) EP1395587B1 (es)
JP (1) JP2005508860A (es)
KR (1) KR20040002973A (es)
CN (1) CN1694885A (es)
AR (1) AR035978A1 (es)
AT (1) ATE437879T1 (es)
BR (1) BR0209842A (es)
CA (1) CA2447227A1 (es)
DE (1) DE60233130D1 (es)
DK (1) DK1395587T3 (es)
EA (1) EA007252B1 (es)
ES (1) ES2328117T3 (es)
MX (1) MXPA03010498A (es)
NO (1) NO20035136D0 (es)
PL (1) PL370705A1 (es)
PT (1) PT1395587E (es)
WO (1) WO2002094828A1 (es)
ZA (1) ZA200308958B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462712B2 (en) * 2001-05-18 2008-12-09 Ranbaxy Laboratories Limited Process for the preparation of imipenem
KR100667373B1 (ko) * 2003-12-09 2007-01-10 주식회사 중외제약 이미페넴의 신규 제조방법
WO2006035300A2 (en) * 2004-09-30 2006-04-06 Ranbaxy Laboratories Limited A process for the preparation of meropenem
WO2010146449A1 (en) * 2009-06-18 2010-12-23 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of imipenam
CN101921275B (zh) * 2010-07-16 2012-09-26 深圳市海滨制药有限公司 一种制备亚胺培南的方法
CN101921273B (zh) * 2010-07-16 2012-09-26 深圳市海滨制药有限公司 一种制备亚胺培南的方法
CN101921274B (zh) * 2010-07-16 2012-09-26 深圳市海滨制药有限公司 一种制备亚胺培南的方法
EP2946006B1 (en) 2013-01-18 2019-04-10 Codexis, Inc. Engineered biocatalysts useful for carbapenem synthesis
CN110790765B (zh) * 2018-08-02 2022-08-05 江苏瑞科医药科技有限公司 一种亚胺培南的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4292436A (en) 1980-06-25 1981-09-29 Merck & Co., Inc. Process for the preparation of N-protected N-formimidoyl 2-aminoethanethiol
US4745188A (en) * 1980-11-21 1988-05-17 Merck & Co., Inc. Process for preparing 3-substituted-6-substituted-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
US4374772A (en) * 1981-03-19 1983-02-22 Merck & Co., Inc. Process for the preparation of N-formimidoyl thienamycin and reagents therefor
US4640915A (en) * 1982-03-29 1987-02-03 Fujisawa Pharmaceutical Co., Ltd. 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid derivatives
US4644061A (en) * 1982-09-28 1987-02-17 Bristol-Myers Company Carbapenem antibiotics
US4782051A (en) * 1985-06-10 1988-11-01 Merck & Co., Inc. 2-aza-substituted 1-carbadethiapen-2-em-3 carboxylic acids
US4894450A (en) * 1987-05-11 1990-01-16 Merck & Co., Inc. Process for 2-(aminoalkylthio) carbapenems
US5672701A (en) * 1990-01-16 1997-09-30 Bristol-Myers Squibb Company 4-substituted alkyl carbapenem antibiotics
US5608056A (en) * 1992-04-13 1997-03-04 Fujisawa Pharmaceutical Co., Ltd. Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents
US5245069A (en) * 1992-10-27 1993-09-14 Merck & Co., Inc. Process for the preparation of bis(aryl)-phosphorohalidates
IN191798B (es) * 2000-11-03 2004-01-03 Ranbaxy Lab Ltd
SK15092003A3 (sk) * 2001-05-18 2004-09-08 Ranbaxy Laboratories Limited Spôsob izolácie kryštalického imipenému
US7462712B2 (en) * 2001-05-18 2008-12-09 Ranbaxy Laboratories Limited Process for the preparation of imipenem
KR100667373B1 (ko) * 2003-12-09 2007-01-10 주식회사 중외제약 이미페넴의 신규 제조방법

Also Published As

Publication number Publication date
MXPA03010498A (es) 2004-05-27
CN1694885A (zh) 2005-11-09
EA200301224A1 (ru) 2004-12-30
EP1395587B1 (en) 2009-07-29
ES2328117T3 (es) 2009-11-10
PL370705A1 (en) 2005-05-30
EP1395587A1 (en) 2004-03-10
EP1395587A4 (en) 2004-09-15
KR20040002973A (ko) 2004-01-07
EA007252B1 (ru) 2006-08-25
PT1395587E (pt) 2009-09-03
DE60233130D1 (de) 2009-09-10
ZA200308958B (en) 2004-07-19
BR0209842A (pt) 2005-01-04
ATE437879T1 (de) 2009-08-15
NO20035136D0 (no) 2003-11-18
WO2002094828A1 (en) 2002-11-28
US7462712B2 (en) 2008-12-09
JP2005508860A (ja) 2005-04-07
US20040220168A1 (en) 2004-11-04
CA2447227A1 (en) 2002-11-28
DK1395587T3 (da) 2009-10-12

Similar Documents

Publication Publication Date Title
MX2007004763A (es) Acidos carboxilicos (bifenilo) y derivados de los mismos.
BRPI0513750A (pt) 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek
YU57599A (sh) Primena derivata fumarne kiseline
AR035978A1 (es) Proceso para preparar imipenem
MY148953A (en) Substituted biphenyl carboxylic acids and derivatives thereof
ATE552907T1 (de) Verfahren zur carbonylierung ethylenisch ungesättigter verbindungen und zugehöriger katalysator
ATE422884T1 (de) Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
ATE353903T1 (de) Kristalline cefdinirsalze
NO20005903L (no) Karboksylsyrer og karboksylsyreisosterer av N-heterosykliske forbindelser
DE69937143D1 (de) Verfahren zur reinigung eines cephalosporin-derivats
DE60118593D1 (de) Verfahren zur herstellung von kristallinem n-formimidoylthienamycin-monohydrat (imipenem-monohydrat)
BRPI0013751B8 (pt) processo para produção de derivados de ácido naftiridina-3-carboxílico.
MXPA04000485A (es) Uso de acidos aril o heteroaril hidroxamicos de sulfonilo y derivados de los mismos como inhibidores de agrecanasa.
MX2010004261A (es) Acidos carboxilicos bifenil y derivados de los mismos.
DE60233307D1 (de) Verfahren zur herstellung optisch aktiver propoxyanilinderivate
TW200613282A (en) Organic compounds
SE9903345D0 (sv) Novel process
BR0316464A (pt) Métodos para preparar e purificar um composto
DE50110250D1 (de) Verfahren zur herstellung von 3-aminoalkansäureestern
WO2003063858A3 (fr) Derives de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires
ATE286539T1 (de) Verfahren zur herstellung von optisch aktiven 3,3,3- trifluormethyl- 2- alkylpropionsäurederivaten
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE256700T1 (de) Verfahren zur herstellung von l-prolyl-l-m- sarcolysyl-l-p-fluorphenylalanin und von derivaten davon
SV1999000144A (es) Procedimientos para preparar sales de trovafloxacina de adicion de acidos ref. pc10011abcz
UA94574C2 (ru) (бифенил) карбоновые кислоты и их производные

Legal Events

Date Code Title Description
FA Abandonment or withdrawal